Innate Pharma Ownership
| IPHA Stock | USD 1.95 0.07 3.47% |
Innate |
Innate Stock Ownership Analysis
The company recorded a loss per share of 0.46. Innate Pharma had not issued any dividends in recent years. Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company was incorporated in 1999 and is headquartered in Marseille, France. Innate Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 213 people. To learn more about Innate Pharma call Mondher MD at 33 4 30 30 30 30 or check out https://www.innate-pharma.com.Innate Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Innate Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Innate Pharma backward and forwards among themselves. Innate Pharma's institutional investor refers to the entity that pools money to purchase Innate Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Exchange Traded Concepts, Llc | 2024-12-31 | 77.3 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 43.5 K | Citadel Advisors Llc | 2024-12-31 | 11.9 K | Ubs Group Ag | 2024-12-31 | 3.5 K | Rhumbline Advisers | 2024-12-31 | 675 | Barclays Plc | 2024-12-31 | 307 | Steward Partners Investment Advisory, Llc | 2024-12-31 | 200 | Optiver Holding B.v. | 2024-12-31 | 101 |
Innate Pharma Outstanding Bonds
Innate Pharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Innate Pharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Innate bonds can be classified according to their maturity, which is the date when Innate Pharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US45782BAD64 Corp BondUS45782BAD64 | View | |
| Installed Building Products Corp BondUS45780RAA95 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Innate Pharma Corporate Filings
6K | 27th of February 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 11th of September 2024 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Innate Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Innate Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Innate Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Innate Pharma Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innate Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Innate Pharma. If investors know Innate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Innate Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.75) | Earnings Share (0.46) | Revenue Per Share | Quarterly Revenue Growth (0.69) | Return On Assets |
The market value of Innate Pharma is measured differently than its book value, which is the value of Innate that is recorded on the company's balance sheet. Investors also form their own opinion of Innate Pharma's value that differs from its market value or its book value, called intrinsic value, which is Innate Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Innate Pharma's market value can be influenced by many factors that don't directly affect Innate Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Innate Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Innate Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Innate Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.